Prodan, C. I., Monnot, M., Ross, E. D.

Frontotemporal dementia (FTD) consists of three main clinical syndromes: (1) frontal variant FTD presenting predominantly with behavioral abnormalities, (2) semantic dementia presenting with fluent aphasic deficits and (3) primary progressive aphasia presenting with non-fluent aphasic deficits. We have observed that significant behavioral problems may occur in some patients with semantic dementia when both comprehension and […]

Finger, E. C., MacKinley, J., Blair, M., Oliver, L. D., Jesso, S., Tartaglia, M. C., Borrie, M., Wells, J., Dziobek, I., Pasternak, S., Mitchell, D. G. V., Rankin, K., Kertesz, A., Boxer, A.

Objective: To determine the safety and tolerability of 3 doses of intranasal oxytocin (Syntocinon; Novartis, Bern, Switzerland) administered to patients with frontotemporal dementia (FTD). Methods: We conducted a randomized, parallel-group, double-blind, placebo-controlled study using a dose-escalation design to test 3 clinically feasible doses of intranasal oxytocin (24, 48, or 72 IU) administered twice daily for […]

Alberici, A., Archetti, S., Pilotto, A., Premi, E., Cosseddu, M., Bianchetti, A., Semeraro, F., Salvetti, M., Muiesan, M. L., Padovani, A., Borroni, B.

Frontotemporal dementia (FTD) is one of the most important neurodegenerative conditions and Granulin (GRN) is one of the major genes associated to the disease. FTD-GRN patients are still orphan for any evidence-based target-therapy approach. Interestingly, it has been recently found that alkalizing agents rescued haploinsufficiency in cellular models expressing FTD-GRN mutations. We set up a […]